-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KTaSKZigyH6dmStuL+YyP1f+nSOYjLtm3yk+w4ywaTlsG0iv5pjZYexBwxQF2T29 C2hDT7xU+AxKxMNWTYX3Dw== /in/edgar/work/20000810/0000950170-00-001260/0000950170-00-001260.txt : 20000921 0000950170-00-001260.hdr.sgml : 20000921 ACCESSION NUMBER: 0000950170-00-001260 CONFORMED SUBMISSION TYPE: 10KSB/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19991231 FILED AS OF DATE: 20000810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OMNICOMM SYSTEMS INC CENTRAL INDEX KEY: 0001034592 STANDARD INDUSTRIAL CLASSIFICATION: [6770 ] IRS NUMBER: 113349762 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10KSB/A SEC ACT: SEC FILE NUMBER: 000-25203 FILM NUMBER: 690850 BUSINESS ADDRESS: STREET 1: 3250 MARY STREET STREET 2: SUITE 402 CITY: MIAMI STATE: FL ZIP: 33133 BUSINESS PHONE: 7184693132 MAIL ADDRESS: STREET 1: 3250 MARY STREET STREET 2: SUITE 307 CITY: MIAMI STATE: FL ZIP: 33133 FORMER COMPANY: FORMER CONFORMED NAME: CORAL DEVELOPMENT CORP DATE OF NAME CHANGE: 19970225 10KSB/A 1 0001.txt FORM 10-KSB/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ---------------------- [Mark One] [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 1999 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to_____________ Commission file number: 0-25203 OmniComm Systems, Inc. ---------------------- (Name of small business issuer in its charter) Delaware 11-3349762 -------- ---------- (State of incorporation) (IRS employer Ident. No.) 3250 Mary Street, Suite 402, Miami, FL 33133 --------------------------------------- ----- (Address of principal office) (Zip Code) Issuer's telephone number: (305) 448-4700 Securities registered under Section 12(b) of the Exchange Act: None ---- Securities registered under Section 12(g) of the Exchange Act: Common Stock, $.001 ------------------- (Title of class) Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes __X_ No_____. Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B not contained in this form, and no disclosure will be contained, to the best of Registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or amendment to this Form 10-KSB. [ ] State issuer's revenues for its most recent fiscal year. $1,259,214 State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of a specified date within the past 60 days. $24,000,000 The number of shares outstanding of each of the issuer's classes of common equity, as of December 31, 1999: 3,344,066. The number of shares outstanding of the issuer's class of preferred equity (5% Series A Convertible Preferred), as of December 31, 1999: 4,117,500. PART III ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTER AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT. Peter S. Knezevich, 43, Chief Executive Officer and Director. Mr. Knezevich served as a Director of the Company from 1998 until his resignation on August 1, 2000. From 1998 until May 29, 2000 Mr. Knezevich was an officer of OmniComm Systems, Inc. From 1995 until 1997 Mr. Knezevich was Vice President and General Counsel for Imaging Diagnostic Systems, Inc. Randall G. Smith, 42, Chief Technical Officer, Chairman of the Board and Director. Mr. Smith has been a Director of the Company since 1997 and shall serve until the next annual meeting. From 1997 until the August 1, 2000 Mr. Smith was President of the Company he is still an officer and director of OmniComm Systems, Inc. From December 1995 to May 1997 Mr. Smith was Director of Operations for Global Communications Group. Clifton Middleton, 52, Executive Vice President. Mr. Middleton is the Executive Vice President responsible for Internet Applications. He has served in this capacity since June of 1998. From 1993 to June of 1998 Mr. Middleton was President of Education Navigator, Inc. Cornelis F. Wit, 54, Director. Mr. Wit has been a Director of the Company since 1999 and shall serve until the next annual meeting. Mr. Wit became interim Chief Executive Officer of the Company on May 29, 2000 and served in that capacity until August 2, 2000. Mr. Wit is President of Corporate Finance of Noesis Capital Corp., an international banking and money management firm. Mr. Wit was formerly President and CEO of DMV Inc., the North American subsidiary of Campina Melkunie. Guus van Kesteren, 59, Director. Mr. Van Kesteren has been a Director of the Company since 1999 and shall serve until the next annual meeting. Mr. Van Kesteren is a consultant to Noesis Capital Corp., an international banking and money management firm. Mr. van Kesteren was formerly Vice President of Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, responsible for the pharmaceutical business in South East Asia, Australia, and New Zealand. Jan Vandamme, 40, Director. Mr. Vandamme has been a Director of the Company since 1999 and shall serve until the next annual meeting. Mr Vandamme is CEO of Profrigo SA, an 110-year old investment company which invests primarily in internet and communication technology companies in both Europe and the US. Prior to his involvement in Profrigo SA, Mr. Vandamme was the founder of United Callers, one of Europe's first Internet Access and Service Provider companies. 2 COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT. Section 16(a) of the Securities and Exchange Act of 1934 (the "Exchange Act") requires our officers and directors, and persons who own more than 10% of the registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission (the "SEC"). Officers, directors and greater than 10% shareholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. Based on our review of the copies of such forms received by us, or written representations from certain reporting persons that no Forms 5 were required for those persons, we believe that, during our fiscal year ended December 31, 1999, all filing requirements applicable to our officers and directors and greater than 10% beneficial owners were complied with, except that (1) Mr. Knezevich unknowingly failed to timely file a Form 4 for a transaction in June 1999 and November 1999, but has since filed a Form 5 covering these transactions;(2) Mr. Smith unknowingly failed to timely file a Form 4 for a transaction in June 1999 and November 1999, but has since filed a Form 5 covering these transactions; and, (3) Mr. Middleton unknowingly failed to timely file a Form 4 for a transaction in June 1999 and November 1999, but has since filed a Form 5 covering these transactions . ITEM 10. EXECUTIVE COMPENSATION SUMMARY COMPENSATION TABLE Long Term Annual Compensan- tion Awards Payouts Name Securities All And Other Restricted Underlying Other Principal Bonus Annual Stock Options/SARs LTIPPayouts Comp Position Year Salary($)($) Comp($) Award(s)($) (#) ($) ($) (a) (b) (c) (d) (e) (f) (g) (h) (i) Peter S. Knezevich 897,568/ CEO/Dir 1999 $84,278 $11,155 897,568 1998 $29,000 Randall G. Smith 732,107/ Pres/Dir 1999 $84,278 $6,205 732,107 1998 $29,000 Clifton Middleton 534,113/ Exec.VP 1999 $91,358 $6,237 534,113 1998 $85,000 3 OPTION/SAR GRANTS IN LAST FISCAL YEAR (Individual Grants) Percent of Total Options/SARs Number of Securities Granted to Exercise of Underlying Employees In Base Price Expiration Name Options/SARs Granted Fiscal Year ($/Sh) Date (a) (#) (b) (c) (d) (e) Peter S. Knezevich 397,568/397,568 $.25 6/14/04 500,000/500,000 $1.50 11/1/01 Randall G. Smith 397,568/397,568 $.25 6/14/04 334,539/334,529 $1.50 11/1/01 Clifton Middleton 96,652/96,652 $.25 6/25/04 250,000/250,000 $1.50 11/1/01 AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR AND FY-END OPTION/SAR VALUES (Individual Grants) Number of Unexercised Securities Shares Underlying Value of Unexercised Acquired Options/SARs At In-The-Money On FY-End (#) Options/SARs At-FY-End Exercise Value Realized Exercisable/ ($)Exercisable Name (#) ($) Unexercisable Unexercisable (a) (b) (c) (d) (e) Peter S.Knezevich 397,568/397,568 $1,391,488/0 500,000/500,000 0/$1,125,000 Randall G. Smith 397,568/397,568 $1,391,488/0 334,539/334,539 0/$752,713 Clifton Middleton 96,652/96,652 $338,282/0 250,000/250,000 0/$562,500 4 ITEM 11. SECURITY OWNERSHIP BY CERTAIN BENEFICIAL OWNERS AND MANAGEMENT. The following table sets forth information regarding the beneficial ownership of our common stock as of March 29, 2000, with respect to (i) each person know to us to be the beneficial owner of more than 5% of our common stock, (ii) each director, (iii) each executive officer named in the summary Compensation Table, and (iv) all of our directors and officers as a group: Name and Address(1) # of Shares(2) % of Class - ------------------- -------------- ---------- Randall G. Smith(3) 811,929 24.28% Peter S. Knezevich(4) 647,108 19.35% Clifton Middleton(5) 197,388 5.90% Cornelis F. Wit 0 0% Guus van Kesteren 0 0% Jan Vandamme 0 0% Hugh McCallum(6) 194,626 5.82% Profrigo SA NV(7) 400,000 11.96% Noesis NV 300,000 8.97% Water Oak Int. NV 295,666 8.84% Everest Investment(8) 416,667 12.46% All directors and Officers as a group (6 people) (9) 1,656,425 49.53% - ------------------------------------------------------------------------------- (1) The address for each person, unless otherwise noted, is 3250 Mary Street, Suite 402, Miami, Florida 33133. (2) In accordance with Rule 13d-3 of the Exchange Act, shares that are not outstanding, but that are subject to options, warrants, rights or conversion privileges exercisable within 60 days from March 29, 2000. (3) Includes 421,461 shares held of record, and 390,648 shares issuable upon the exercise of currently exercisable stock options. (4) Includes 256,640 shares held of record, and 390,648 shares issuable upon the exercise of currently exercisable stock options. (5) Includes 102,461 shares held of record, and 94,927 shares issuable upon the exercise of currently exercisable stock options. (6) Includes 102,461 shares held of record, and 92,165 shares issuable upon the exercise of currently exercisable stock options. (7) Represents the number of shares issuable upon conversion of the Series A Convertible Preferred Shares. 5 (8) Includes 266,667 shares issuable upon conversion of the Series A Convertible Preferred Shares. (9) See Notes 3 through 5 above. ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS. On December 16, 1999, the Company entered into a consulting agreement ("Agreement") with Guus van Kesteren and Cornelis F. Wit both of whom are directors of the Company. The Agreement provides for compensation to be paid to van Kesteren and Wit in the event sales leads or contacts developed by van Kesteren and Wit result in sales of the Company's TrialMaster(TM) system. ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K (a) Exhibits 10 (g) Consulting Agreement dated December 16, 2000 by and between OmniComm Systems, Inc. and Cornelis F. Wit and Guus van Kesteren 6 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, OmniComm Systems, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, By: /s/Randall G. Smith ------------------- Randall G. Smith Chairman and President (Through August 1, 2000) and Chief Technical Officer Date: August 8, 2000 Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated. By: /s/ Randall G. Smith --------------------------- Randall G. Smith Chairman and President (Through August 1, 2000) and Chief Technical Officer Date: August 8, 2000 By: /s/ Guus van Kesteren --------------------------- Guus van Kesteren Director Date: August 8, 2000 By: /s/ Cornelis F. Wit --------------------------- Cornelis F. Wit Director Dated: August 8, 2000 By: /s/ Jan Vandamme --------------------------- Jan Vandamme Director Date: August 8, 2000 7 EXHIBIT INDEX Exhibit No. Description - ----------- ----------- 10 (g) Consulting Agreement dated December 16, 2000 by and between OmniComm Systems, Inc. and Cornelis F. Wit and Guus van Kesteren EX-10.(G) 2 0002.txt Exhibit 10.(g) Consulting Agreement CONSULTING AGREEMENT This Consulting Agreement (the "Agreement") is made as of December 16, 1999, by and between OmniComm Systems, Inc., a Delaware corporation (hereinafter referred to as "Company"), and Cees Wit and/or Guus van Kesteren (hereinafter collectively referred to as "Consultant"). RECITALS: Whereas, the Company is in the business of developing and implementing a web-based application for the remote collection, compilation, and management of clinical trial data and clinical trials ("TrialMasterTM"); and Whereas, the Consultant has certain expertise in and has established relationships with companies and institutions involved in conducting clinical trials; and Whereas, the Company desires to retain the Consultant, and Consultant desires to be retained by the Company, upon the following terms and conditions. Now Therefore, in consideration of the mutual promises and conditions contained herein, the parties agree to be legally bound as follows: 1. Status of Consultant. The Consultant for purposes of this Agreement shall be considered an independent consultant. The Company is not responsible for withholding, and shall not withhold, FICA or taxes of any kind from any payments that it owes the Consultant. The Consultant shall not be entitled to receive any benefits which employees of the Company are entitled to receive and shall not be entitled to workers' compensation, unemployment compensation, medical insurance, life insurance, paid vacations, paid holidays, pension, profit sharing, or Social Security on account of their work for the Company. 2. Nature of Consultancy. Consultant shall assist the Company in the marketing and promotion of TrialMasterTM and shall use his relationships within the medical device and drug industry to develop sales leads and introductions. Any introductions developed by Consultant shall be at the level of Director of Clinical Research, or equivalent position, or at a level immediately below that position. 3. Efforts of Consultant. While acting as a consultant for the Company, the Consultant shall devote his best efforts and skill to the performance of his duties as a Consultant to the Company. 4. Notification. The Consultant shall notify the Company in writing of any individuals, companies or institutions that the Consultant has contacted concerning the TrialMaster(TM) system ("Notified Party"). The written notification shall contain the name of the company or institution, person contacted, and a general description of the company's or institution's core business. Compensation shall be owed only for transactions involving a Notified Party. If a meeting between the Company and the Notified Party does not take place within one hundred and twenty (120) days of the Company being notified of the existence of the Notified Party the individual and company shall cease to be a Notified Party for all purposes including compensation. The initial Notified Parties are attached hereto as Exhibit A as if incorporated herein. 5. Compensation. The Consultant shall be paid a commission set forth below based on the net invoice price of all products and services sold to a Notified Party. In the event there is recurring revenue from a Notified Party, the commission paid shall be recalculated as follows: (a) 1st Year: 20% (b) 2nd Year: 10% (c) 3rd Year: 8% (d) 4th Year: 7.5% (e) 5th Year: 5% At the conclusion of the fourth year no further compensation will be due or owing. Payment shall be due and paid within fifteen (15) days of the end of the calendar quarter. The Company may, in its sole and absolute discretion, remit funds earlier. The Company shall provide to the Consultant within 90 days of the end of the Company's fiscal year audited financial information concerning the revenues generated from the Notified Parties. 6. Expenses. The Company agrees to reimburse Consultant for any and all expenses incurred in the course of providing services under this Agreement if the expenses have been submitted and approved in writing in advance of being incurred. 7. Term. The term of this Agreement shall commence on the date initially set forth above and shall continue for one (1) year (the "Initial Term"), with subsequent one (1) year renewal periods ("Renewal Term"), unless either party chooses to terminate this Agreement by giving notice at least 90-days prior to the beginning of a Renewal Term. 8. Termination by Consultant or Company. Either party shall have the right in their sole and absolute discretion to terminate the Agreement after the Initial Term and their respective rights and obligations on ninety (90) days written notice, except compensation shall be paid in accordance with the terms and conditions of this Agreement. 9. Disclosure of Confidential Business and Technical Information. The Consultant recognizes and acknowledges that the Company's trade secrets and proprietary information and processes, ("Confidential Business and Technical Information") as they may exist from time to time, are valuable, special and unique assets of the Company's business, access to and knowledge of which are essential to the performance of the Consultant's duties hereunder. The Consultant will not, during or after the term of his employment by the Company, in whole or in part, disclose such Confidential Business and Technical Information to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, nor shall the Consultant make use of any such Confidential Business and Technical Information for his own purposes or for the benefit of any person, firm, corporation or other entity except the Company under any circumstances during or after the term of his employment, provided that after the term of his employment these restrictions shall not apply to such secrets, information and processes which are then in the public domain provided that the Employee was not responsible, directly or indirectly, for such secrets, information or processes entering the public domain without the Company's consent. In the event an action is instituted and prior knowledge is an issue, it shall be the obligation of the Employee to prove by clear and convincing evidence that the Confidential Business and Technical Information disclosed was in the public domain, was already known by the Consultant, or was developed independently by the Consultant. The Consultant agrees to hold as the Company's property, all memoranda, books, papers, letters, formulas and other data, and all copies thereof and therefrom, in any way relating to the Company's business and affairs, whether made by him or otherwise coming into his possession, and on termination of his employment, or on demand of the Company, at any time, to deliver the same to the Company. 10. Inventions. The Consultant hereby sells, transfers and assigns to the Company or to any person, or entity designated by the Company, all of the entire right, title and interest of the Consultant in and to all inventions, ideas, disclosures and improvements, whether patented or unpatented, and copyrightable material, made or conceived by the Consultant specifically for the Company or at the Company's premises, solely or jointly, or in whole or in part, during the term hereof which (i) relate to methods, apparatus, designs, products, processes or devices sold, leased, used or under construction or development by the Company or any subsidiary, or (ii) otherwise relate to or pertain to the business, functions or operations of the Company or any subsidiary. The Consultant shall communicate promptly and disclose to the Company, in such form as the Company requests, all information, details and data pertaining to the aforementioned inventions, ideas, disclosures and improvements; and, whether during the term hereof or thereafter, the Consultant shall execute and deliver to the Company such formal transfers and assignments and such other papers and documents as maybe required of the Consultant at the Company's expense to permit the Company or any person or entity designated by the Company to file and prosecute the patent applications and, as to copyrightable material, to obtain copyright thereon. 11. Covenant Not to Compete. During the term of this Agreement the Consultant shall not, directly or indirectly, be employed or retained by an individual or entity or involved in any activity that is involved in or with the development of an application that is the subject of this Agreement. 12. Remedies. If there is a breach or threatened breach of Section(s) 9, 10, or 11 of this Agreement, the Company shall be entitled to an injunction restraining the Consultant from such breach. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies for such breach or threatened breach. 13. GENERAL PROVISIONS 13.1 Invalidity of Provisions. In the event that any provision or portion of a provision of this Agreement shall be held to be unreasonable or unenforceable, such unenforceability shall attach to such provision or portion thereof only to the extent of the specific finding of unenforceability, and in all other respects such provision or portion thereof shall be deemed enforceable, it being the intention of the parties that this Agreement be construed in all respects as if such invalid or unenforceable provision were omitted. 13.2 Non-Assignability. This Agreement is personal and shall not be assigned by Consultant. This Agreement may be assigned by the Company to any person or entity that acquires the entire assets of the Company 13.3 Applicable Law and Forum. The validity, construction and effect of this Agreement and the respective rights and obligations of the parties hereunder, shall be governed by and determined in accordance with the laws of the state of Florida in the United States of America as such laws are applied to contracts between Florida residents entered into and to be performed entirely within the state of Florida, without reference to principles of conflicts of law. All actions and proceedings arising out of or relating to this Agreement shall be heard and determined in a state or federal court sitting in the County of Dade, State of Florida. Service of process shall be considered effective if done pursuant to any of the methods set forth in Rule 4(i), Federal Rule of Civil Procedure or pursuant to Florida law. 13.4 Waiver of Breach. The waiver by Company of breach of any provision of this Agreement by Consultant shall not operate or be construed as a waiver of any subsequent breach by Consultant. 13.5 Entire Understanding. This Agreement shall constitute the entire understanding between the parties with reference to the subject matter hereof, shall supersede all prior understandings or agreements, whether oral or written and shall not be altered, modified, or discharged except in a writing signed by the parties. 13.6 Benefit of Parties. Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit of Consultant and his personal representatives and the Company, its successors and permitted assigns. 13.7 Right to Contract. The parties represent and warrant that each has the right to enter into this Agreement and to assume all obligations and grant all rights herein and that Consultant has neither made nor will make any contractual or other commitments that are in conflict with this Agreement. 13.8 Litigation. In the event of any cause of action, arbitration or litigation arising hereunder, all costs and reasonable attorney's fees of the prevailing party, including, without limitation, attorney's fees and costs at all administrative and appellate levels and in all bankruptcy proceedings, shall be paid by the other party. 13.9 Counterparts. This Agreement may be executed in any number of counterparts, all of which shall be deemed to be an original, but all of which shall be deemed to constitute but one instrument. 13.10 Confidentiality of Relationship. The existence of the relationship between the Company and the Consultant, the Agreement, and any other matters relating to the relationship between the Company and the Consultant shall not be disclosed to any party unless written authorization is given by the Consultant prior to such disclosure. 13.11 Assignment and Third Parties. The Consultant will assign this Agreement to third parties. No additional compensation or fees shall be paid to a third party. [INTENTIONALLY LEFT BLANK-SIGNATURE PAGE FOLLOWS] IN WITNESS WHEREOF, the parties hereto have set there hands the day and year first above written. Consultant /s/Cees Wit - ----------- Cees Wit /s/Guus van Kesteren - -------------------- Guus van Kesteren OmniComm Systems, Inc. By:/s/Peter S. Knezevich --------------------- Peter S. Knezevich Chief Executive Officer Exhibit A To Consulting Agreement Notified Parties
COMPANY/INSTITUTION PERSON CONTACT CORE BUSINESS - ------------------- -------------- ------------- Amgen-USA Pharma Ares Serono-Switzerland Dr. Patrick Engrand-Biostatistician Pharma Clifden Healthcare Ltd.-UK Dr. C. Mugglestone/T. Anscomb-Partners CRO Covance-USA Dr. John Mills-Corporate VP and Gen. Mgr. CRO Croda-UK Dr. Keith Layden-Man. Dir. Croda Leek Chemicals/OTC/Pharma GlaxoWellcome K. Roosjen-VP Northern Europe Pharma Health Care Consultancy Group-Switzerl. Urs W. Eggimann-Man. Dir. Pharma Consultancy R. Herreman-Belgium R. Herreman Pharma/Hospital supplies/Investor Hoechst-Germany Dr.T. Kiy-R&D Technology Mgr. Pharma IMS-Netherlands Jan Hein Lans-Gen. Mgr. Pharma Market info Innogenetics-Belgium Paul Appermont-VP Bus. Devt+Operations Pharma J & C Management Co., Inc.-USA Dr. Cliff Siporin-CEO CRO Janssen Pharmaceutica-Belgium Dr. G. Van Reet-President Pharma Johnson&Johnson-USA Robert Coradini-VP Bus. Devt. Professional Devices Kent Ollson-Sweden Kent Ollson-owner Pharma Consultancy Knoll Pharma-Germany Prof. Schlick-VP R&D Pharma Maxxim-Netherlands Rob W. Beek-VP Europe Hospital supplies MediSearch Int.'l-Belgium Dr.Remi Van Den Broeck-Man. Dir. CRO Organon-Netherlands Dr. D. Vergauwen-VP R&D Pharma Quintiles-USA Anne Wiles-Exec. V.P. Bus. Devt. CRO Rijks Universiteit Leiden-Netherlands Prof. J.M. Wit-Chairman Pediatrics Pediatrics Scotia-UK Dr. D. Selkirk-VP R&D Pharma Solvay-Belgium B. Quist-VP Bus. Devt. Pharma South Fla. Gastro. Interology Grp. Dr. Lopez IPA
-----END PRIVACY-ENHANCED MESSAGE-----